Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Johnson and Johnson
McKinsey
Harvard Business School
Medtronic

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR ETOMIDATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Etomidate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00175747 ↗ A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed National Cancer Institute (NCI) Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00175747 ↗ A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) Completed University of British Columbia Phase 2/Phase 3 2000-01-01 Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.
NCT00248729 ↗ Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital. Completed St. Luke's Hospital, Pennsylvania Phase 2 2002-10-01 The objective of this study was to compare the utility of etomidate and midazolam in helping patients to relax when there was a need for the placement of a ventilation tube by medics who were transporting patients to a hospital in an ambulance.
NCT00415701 ↗ Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed University Hospital Inselspital, Berne Phase 4 2006-11-01 The purpose of this study is to evaluate the effect of a single dose of etomidate for patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB adrenocortical responsiveness, on requirements of hemodynamic support, and on use of intensive care resources.
NCT00440102 ↗ Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity Completed Assistance Publique - Hôpitaux de Paris Phase 4 2007-04-01 The expected benefit is a reduction of the morbidity of patients admitted in the intensive care unit having received ketamine for intubation.
NCT00441792 ↗ The Effect of Etomidate on Patient Outcomes After Single Bolus Doses Completed Emergency Medicine Foundation N/A 2007-10-01 The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.
NCT00441792 ↗ The Effect of Etomidate on Patient Outcomes After Single Bolus Doses Completed Advocate Hospital System N/A 2007-10-01 The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etomidate

Condition Name

Condition Name for Etomidate
Intervention Trials
Anesthesia 7
Depression 4
Coronary Artery Disease 4
General Anesthesia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Etomidate
Intervention Trials
Depression 7
Depressive Disorder 6
Depressive Disorder, Major 5
Coronary Artery Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Etomidate

Trials by Country

Trials by Country for Etomidate
Location Trials
United States 26
China 15
France 6
Korea, Republic of 4
Poland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Etomidate
Location Trials
Pennsylvania 3
Minnesota 3
California 2
Tennessee 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Etomidate

Clinical Trial Phase

Clinical Trial Phase for Etomidate
Clinical Trial Phase Trials
Phase 4 43
Phase 3 8
Phase 2/Phase 3 4
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Etomidate
Clinical Trial Phase Trials
Completed 43
Unknown status 20
Recruiting 15
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Etomidate

Sponsor Name

Sponsor Name for Etomidate
Sponsor Trials
Tianjin Medical University General Hospital 3
The Cleveland Clinic 3
Henan Provincial People's Hospital 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Etomidate
Sponsor Trials
Other 104
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
Johnson and Johnson
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.